Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

Contributed by: PR Newswire

Tags

Sironax-Novartis-acq

More Like This

PR Newswire associated0

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

PR Newswire associated0

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

PR Newswire associated0

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs